We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

51 hedge funds and large institutions have $98.3M invested in VanEck Pharmaceutical ETF in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

14.95% less ownership

Funds ownership: 52.45% → 37.51% (-15%)

15% less funds holding

Funds holding: 60 → 51 (-9)

35% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 17

45% less capital invested

Capital invested by funds: $177M → $98.3M (-$79.2M)

Holders
51
Holders Change
-9
Holders Change %
-15%
% of All Funds
1.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
15
Reduced
13
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$13.4M
2
Bank of America
Bank of America
North Carolina
+$4.87M
3
UBS Group
UBS Group
Switzerland
+$4.2M
4
CC
Colrain Capital
Massachusetts
+$2.44M
5
Morgan Stanley
Morgan Stanley
New York
+$1.46M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$66.8M
2
Citigroup
Citigroup
New York
-$16M
3
LFM
Lumina Fund Management
New York
-$3.7M
4
VF
Virtu Financial
New York
-$2.32M
5
AL
Aspiriant LLC
California
-$1.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
LFM
51
Lumina Fund Management
New York
– -$3.7M -64,400 Closed
VF
52
Virtu Financial
New York
– -$2.32M -40,385 Closed
AL
53
Aspiriant LLC
California
– -$1.7M -29,495 Closed
WIC
54
Woodmont Investment Counsel
Tennessee
– -$1.37M -23,775 Closed
Jane Street
55
Jane Street
New York
– -$508K -8,845 Closed
LCM
56
LVM Capital Management
Michigan
– -$477K -7,685 Closed
VKH
57
Virtu KCG Holdings
New York
– -$376K -6,548 Closed
SG Americas Securities
58
SG Americas Securities
New York
– -$350K -6,095 Closed
KFC
59
Klingenstein Fields & Co
New York
– -$287K -5,000 Closed
NAM
60
NTV Asset Management
West Virginia
– -$278K -4,850 Closed
JWM
61
Jacobus Wealth Management
Wisconsin
– -$274K -4,760 Closed
RCG
62
Ruggie Capital Group
Florida
– -$272K -4,733 Closed
Millennium Management
63
Millennium Management
New York
– -$231K -4,019 Closed
HIIFS
64
Harel Insurance Investments & Financial Services
Israel
– -$78K -1,350 Closed
CG
65
Cutler Group
California
– -$38K -673 Closed
Simplex Trading
66
Simplex Trading
Illinois
– -$15K -272 Closed
CFA
67
Carroll Financial Associates
North Carolina
– -$11K -200 Closed
1 2
3

PPH Hedge Fund Activity: Q4 2016 in Review

51 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2016, worth a combined $98.3M — down 45% from $177M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of PPH and 11 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 15 added.

The largest buyer was JP Morgan Chase, adding an estimated $13.4M. The largest seller was Goldman Sachs, cutting an estimated $66.8M.

  • 51 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2016, down from 60 in Q3 2016.
  • Funds reported $98.3M of VanEck Pharmaceutical ETF stock for Q4 2016, down 45% quarter-over-quarter.
  • 11 funds opened new VanEck Pharmaceutical ETF positions in Q4 2016 and 17 closed out, a net change of -6 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q4 2016 was JP Morgan Chase, an estimated $13.4M added.
  • The largest VanEck Pharmaceutical ETF seller in Q4 2016 was Goldman Sachs, an estimated $66.8M sold.

Based on aggregated 13F filings for Q4 2016.